quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·44d
PRRelease
GeneDx Holdings Corp. logo
Zevra Therapeutics Inc. logo

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

WGS· GeneDx Holdings Corp.ZVRA· Zevra Therapeutics Inc.
TechnologyHealth Care
Original source

Companies

  • WGS
    GeneDx Holdings Corp.
    Technology
  • ZVRA
    Zevra Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 16ZVRAUpdateBTIG Research$23.00
  • Feb 9WGSUpdateWells Fargo$155.00
  • Oct 20WGSUpdateCanaccord Genuity$155.00
  • Jul 9WGSUpdatePiper Sandler$110.00
  • Jul 2ZVRAUpdateH.C. Wainwright$26.00
  • May 15WGSUpdateGuggenheim$88.00

Related

  • PR1d
    Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
  • SEC3d
    SEC Form DEF 14A filed by Zevra Therapeutics Inc.
  • PR10d
    GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026
  • SEC17d
    SEC Form PRE 14A filed by Zevra Therapeutics Inc.
  • INSIDER24d
    SEC Form 4 filed by Feeley Kevin
  • INSIDER24d
    SEC Form 4 filed by Stueland Katherine
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Zevra Therapeutics Inc.
  • INSIDER28d
    SEC Form 4 filed by Bode John B
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022